Josef Karban
- Genetics top 10%
- Chronic Lymphocytic Leukemia Research 22
-
- Lymphoma Diagnosis and Treatment 12
-
- Immunodeficiency and Autoimmune Disorders 7
-
- Chronic Myeloid Leukemia Treatments 4
- Acute Myeloid Leukemia Research 2
-
- Acute Lymphoblastic Leukemia research 4
-
- Cutaneous lymphoproliferative disorders research 2
-
- RNA modifications and cancer 2
Josef Karban
29 papers receiving 297 citations
Peers
Comparison fields: 5 of 49
- Genetics 140
- Cancer Research 90
- Pathology and Forensic Medicine 102
- Immunology 113
- Hematology 26
Countries citing papers authored by Josef Karban
This map shows the geographic impact of Josef Karban's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Josef Karban with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Josef Karban more than expected).
Fields of papers citing papers by Josef Karban
This network shows the impact of papers produced by Josef Karban. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Josef Karban. The network helps show where Josef Karban may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Josef Karban, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 0 | |
| 2 | 2022 | 1 | |
| 3 | 2021 | 2 | |
| 4 | 2020 | 1 | |
| 5 | 2019 | 4 | |
| 6 | 2015 | 21 | |
| 7 | 2014 | 7 | |
| 8 | 2013 | 2 | |
| 9 | 2011 | 117 | |
| 10 | 2010 | 4 | |
| 11 | 2010 | 4 | |
| 12 | 2010 | 4 | |
| 13 | 2010 | 7 | |
| 14 | 2010 | 8 | |
| 15 | 2009 | 19 | |
| 16 | 2005 | 31 | |
| 17 | 2003 | 9 | |
| 18 | [Lymphocyte immunophenotyping and cytogenetics for more precise prognosis in patients with type B chronic lymphatic leukemia]. | 2003 | 2 |
| 19 | [Importance of prognostic factors in patients with chronic B-lymphocytic leukemia at the time of diagnosis]. | 2002 | 5 |
| 20 | [The interphase fluorescence in situ hybridization (I-FISH) technique in patients with chronic lymphatic leukemia (CLL)]. | 2000 | 3 |
About Josef Karban
Josef Karban is a scholar working on Genetics, Hematology and Pathology and Forensic Medicine, having authored 31 papers that have together received 300 indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (22 papers), Lymphoma Diagnosis and Treatment (12 papers), Immunodeficiency and Autoimmune Disorders (7 papers), Chronic Myeloid Leukemia Treatments (4 papers), Acute Lymphoblastic Leukemia research (4 papers), Acute Myeloid Leukemia Research (2 papers), Cutaneous lymphoproliferative disorders research (2 papers) and RNA modifications and cancer (2 papers). The work is most often cited by research in Genetics (140 citations), Cancer Research (90 citations) and Pathology and Forensic Medicine (102 citations). Josef Karban has collaborated with scholars based in Czechia, United States and Germany. Frequent co-authors include Marek Trněný, Adéla Berková, Tomáš Stopka, K Michalová, Zuzana Zemanová, Jana Březinová, Jiřı́ Mayer, Petra Bašová, Juraj Kokavec and Filipp Savvulidi. Their work appears in journals such as Blood, Journal of Cellular Physiology and European Journal Of Haematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.